• 1
    Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55–74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 97580
  • 2
    SEER Cancer Incidence Public-Use Database. CD-ROM 197397 August 1999 Submission. National Cancer Institute, 2000
  • 3
    Lu-Yao GL, Yao S-L. Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet 1997; 349: 90610
  • 4
    SPSS for Windows Release 6.0. SPSS Inc, 444 North Michigan Avenue, Chicago, IL 60611, USA; 1993
  • 5
    Richie JP, Catalona WJ, Ahmann FR et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993; 42: 36574
  • 6
    Rietbergen JBW, Hoedemaeker RF, Kruger AEB, Kirkels WJ, Schröder FH. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol 1999; 161: 11928
  • 7
    Labrie F, Dupont A, Suburu R et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992; 147: 84652
  • 8
    Määttänen L, Auvinen A, Stenman U-H et al. European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999; 79: 12104
  • 9
    Horninger W, Reissigl A, Rogatsch H et al. Prostate cancer screening in Tyrol, Austria: experience and results. Eur Urol 1999; 35: 52338
  • 10
    Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996; 276: 130915
  • 11
    Stanford JL, Stephenson RA, Coyle LM et al. National Cancer Institute. no. 99–4543. Bethesda, MD: NIH Publications, 1999
  • 12
    National Center for Health Statistics. Vital Statistics for the United States, 1992: Mortality, part A. Vol. II. Washington: Public Health Service, 1996
  • 13
    Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152: 17326
  • 14
    Mettlin C, Murphy GP, Lee F et al. Characteristics of prostate cancer detected in the American Cancer Society-National Cancer Detection Project. J Urol 1994; 152: 173740
  • 15
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995; 273: 28994
  • 16
    Parkes C, Wald NJ, Murphy P et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ 1995; 311: 13403
  • 17
    Chodak GW, Thisted RA, Glenn GS et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 2428


  1. Authors

P.W. Nicholson, BSc, PhD, Physicist.

S.J. Harland, MD, MSc, FRCP, Medical Oncologist.


Surveillance, Epidemiology and End Results (programme).